ACT 256.60 Actavis Inc $ACT Hit a 52 week high of
Post# of 91
Posted On: 11/18/2014 10:09:59 AM
ACT 256.60 Actavis Inc $ACT Hit a 52 week high of 256.80 Closing the day 09:45 at 256.60 +8.66 +3.49% With a day low of 249.86 and a total volume of 1,501,240.
ACT Recent Posts: http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
Will Pfizer's Dividend Be Safe?
Todd Campbell, The Motley Fool - Motley Fool - 40 mins ago
Source: Pfizer via Facebook. Pfizer (NYSE: PFE) may be one of the planet's largest drugmakers, but it's been navigating a series of sales-crunching patent expirations that has investors wondering if the company's dividend payout will remain...
ACT: 260.82 (+12.88), PFE: 30.40 (+0.08), TEVA: 58.20 (+0.96)
Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit?
Uncommon Profit Investor - at Seeking Alpha - 1 hr 37 mins ago
AGN: 212.52 (+3.32), VRX: 141.00 (+4.27), ACT: 260.82 (+12.88)
Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 212.52 (+3.32), ACT: 260.82 (+12.88), VRX: 141.00 (+4.27), V: 251.14 (+1.34), ALXN: 191.63 (+4.85), CTSH: 53.15 (+0.09), MA: 83.46 (+0.26), ADS: 280.89 (+0.01)
Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 212.52 (+3.32), ACT: 260.84 (+12.90), AMAG: 35.73 (+0.97), BMY: 58.72 (+0.29)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:40PM CST
URBN: 28.74 (-2.09), DHX: 11.48 (+0.22), ACT: 260.84 (+12.90), OME: 12.71 (-2.27), CLVS: 53.89 (+0.56), AVB: 157.85 (-0.31), PF: 32.46 (-1.26), RMTI: 10.14 (-0.44), GLW: 20.42 (+0.06), FOLD: 6.33 (-0.37)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 212.52 (+3.32), ACT: 260.84 (+12.90), VRX: 140.97 (+4.24), MRK: 59.71 (+0.25), VRX.TO: 159.43 (+5.03)
Stocks End Mixed As Allergan Jumps On Actavis Deal
at Investor's Business Daily - Mon Nov 17, 3:16PM CST
Major averages pared losses from a late-morning slump to end mixed amid big merger deals and weak economic data. The S&P 500 and Dow Jones industrial average closed fractionally higher, while the Nasdaq fell 0.4%. Volume ran lower across the board in...
AGN: 212.52 (+3.32), VRX: 140.97 (+4.24), ACT: 260.85 (+12.91), SAFM: 86.62 (+1.69), PPC: 31.42 (+0.48), MIK: 22.16 (+0.51), TSN: 43.03 (unch)
Stock Market Today: Japan Recession Keeps Markets From Celebrating Deals Deluge
at The Street - Mon Nov 17, 3:15PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies momentarily distracts Wall Street from worrying news Japan has fallen into recession in its third quarter.
AMZN: 326.88 (+3.83), HAS: 56.16 (-0.21), ACT: 260.85 (+12.91), VRX: 140.97 (+4.24), JIVE: 6.37 (unch), FB: 74.56 (+0.32), HAL: 49.90 (+0.67), DWA: 22.59 (+0.28), AGN: 212.52 (+3.32), LNKD: 223.01 (-0.27), BHI: 66.08 (+0.85), CRM: 63.16 (+0.65)
Stocks Mixed In Afternoon; Allergan Jumps To New High
at Investor's Business Daily - Mon Nov 17, 2:13PM CST
Stocks remained mixed late Monday afternoon as investors weighed a spate of merger activity against news that Japan fell into a recession. The Dow Jones industrial average and the S&P 500 were each up 0.1%, while the Nasdaq was down 0.3%. Volume was...
AGN: 212.52 (+3.32), VRX: 140.97 (+4.24), ACT: 261.13 (+13.19), LNKD: 223.20 (-0.08), FB: 74.56 (+0.32), HAL: 49.90 (+0.67), BHI: 66.08 (+0.85), Z: 119.71 (+1.85)
Stock Market Today: Stocks Are Mixed as Corporate Deals Offset Japan's Recession
at The Street - Mon Nov 17, 12:16PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies distract Wall Street from worrying news Japan had fallen into recession in its third quarter.
AGN: 212.69 (+3.49), HAS: 56.16 (-0.21), AMZN: 326.88 (+3.83), VRX: 140.97 (+4.24), ACT: 261.25 (+13.31), LNKD: 223.22 (-0.06), JIVE: 6.37 (unch), FB: 74.56 (+0.32), HAL: 49.90 (+0.67), DWA: 22.59 (+0.28), CRM: 63.16 (+0.65), BHI: 66.08 (+0.85)
Pershing Square wins big on Actavis buy
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:22AM CST
AGN: 212.69 (+3.49), ACT: 261.09 (+13.15), VRX: 140.97 (+4.24)
Cramer: Investors Should Ignore Analysts' Calls on Hotel, Other Stocks
at The Street - Mon Nov 17, 10:32AM CST
Analysts have been growing pessimistic on several high quality stocks and sectors. Investors should use weakness as a buying opportunity instead, Cramer said.
AGN: 212.69 (+3.49), ACT: 261.10 (+13.16), PG: 87.83 (-0.01), MAR: 76.94 (-0.23), HOT: 77.22 (+0.37)
Allergan's $66 Billion Actavis Deal is Still a Win for Bill Ackman
at The Street - Mon Nov 17, 9:59AM CST
Valeant says it can't justify $219 a share offer to shareholders.
ZTS: 44.06 (-0.17), AGN: 212.69 (+3.49), VRX: 140.97 (+4.24), ACT: 261.10 (+13.16)
Stock Market Today: Stocks Shrug Off Japan's Recession as Deals Dominate Day
at The Street - Mon Nov 17, 9:40AM CST
U.S. stocks recover from earlier lows triggered by Japan's recession. Deals news about Baker Hughes and Allergan dominate headlines.
AGN: 212.69 (+3.49), HAS: 56.16 (-0.21), ACT: 261.14 (+13.20), HAL: 49.90 (+0.67), DWA: 22.59 (+0.28), BHI: 66.07 (+0.84)
ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Mon Nov 17, 9:32AM CST
Rigrodsky & Long, P.A.:
AGN: 212.59 (+3.39), ACT: 261.13 (+13.19)
Actavis Nabs Allergan For $66 Billion; Valeant Folds
at Investor's Business Daily - Mon Nov 17, 9:17AM CST
One of the most widely rumored deals in pharma came to fruition Monday, as Actavis (ACT) agreed to acquire Allergan (AGN) for $66 billion in cash and stock. Allergan stock was up more than 7%, near 213, and Actavis stock up nearly 4%, near 253, in...
AGN: 212.68 (+3.48), VRX: 140.97 (+4.24), ACT: 260.76 (+12.82)
Time to move on: Valeant chief says $219 too rich
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 9:13AM CST
ACT: 261.05 (+13.11), VRX: 140.97 (+4.24)
Valeant Comments On Allergan Announcement
PR Newswire - Mon Nov 17, 8:29AM CST
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock.
AGN: 212.68 (+3.48), ACT: 261.05 (+13.11), VRX: 140.97 (+4.24), VRX.TO: 159.49 (+5.09)
It's official: Actavis buys Allergan
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:26AM CST
AGN: 212.68 (+3.48), ACT: 261.07 (+13.13)
ACT Recent Posts: http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
Will Pfizer's Dividend Be Safe?
Todd Campbell, The Motley Fool - Motley Fool - 40 mins ago
Source: Pfizer via Facebook. Pfizer (NYSE: PFE) may be one of the planet's largest drugmakers, but it's been navigating a series of sales-crunching patent expirations that has investors wondering if the company's dividend payout will remain...
ACT: 260.82 (+12.88), PFE: 30.40 (+0.08), TEVA: 58.20 (+0.96)
Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit?
Uncommon Profit Investor - at Seeking Alpha - 1 hr 37 mins ago
AGN: 212.52 (+3.32), VRX: 141.00 (+4.27), ACT: 260.82 (+12.88)
Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 212.52 (+3.32), ACT: 260.82 (+12.88), VRX: 141.00 (+4.27), V: 251.14 (+1.34), ALXN: 191.63 (+4.85), CTSH: 53.15 (+0.09), MA: 83.46 (+0.26), ADS: 280.89 (+0.01)
Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 212.52 (+3.32), ACT: 260.84 (+12.90), AMAG: 35.73 (+0.97), BMY: 58.72 (+0.29)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:40PM CST
URBN: 28.74 (-2.09), DHX: 11.48 (+0.22), ACT: 260.84 (+12.90), OME: 12.71 (-2.27), CLVS: 53.89 (+0.56), AVB: 157.85 (-0.31), PF: 32.46 (-1.26), RMTI: 10.14 (-0.44), GLW: 20.42 (+0.06), FOLD: 6.33 (-0.37)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 212.52 (+3.32), ACT: 260.84 (+12.90), VRX: 140.97 (+4.24), MRK: 59.71 (+0.25), VRX.TO: 159.43 (+5.03)
Stocks End Mixed As Allergan Jumps On Actavis Deal
at Investor's Business Daily - Mon Nov 17, 3:16PM CST
Major averages pared losses from a late-morning slump to end mixed amid big merger deals and weak economic data. The S&P 500 and Dow Jones industrial average closed fractionally higher, while the Nasdaq fell 0.4%. Volume ran lower across the board in...
AGN: 212.52 (+3.32), VRX: 140.97 (+4.24), ACT: 260.85 (+12.91), SAFM: 86.62 (+1.69), PPC: 31.42 (+0.48), MIK: 22.16 (+0.51), TSN: 43.03 (unch)
Stock Market Today: Japan Recession Keeps Markets From Celebrating Deals Deluge
at The Street - Mon Nov 17, 3:15PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies momentarily distracts Wall Street from worrying news Japan has fallen into recession in its third quarter.
AMZN: 326.88 (+3.83), HAS: 56.16 (-0.21), ACT: 260.85 (+12.91), VRX: 140.97 (+4.24), JIVE: 6.37 (unch), FB: 74.56 (+0.32), HAL: 49.90 (+0.67), DWA: 22.59 (+0.28), AGN: 212.52 (+3.32), LNKD: 223.01 (-0.27), BHI: 66.08 (+0.85), CRM: 63.16 (+0.65)
Stocks Mixed In Afternoon; Allergan Jumps To New High
at Investor's Business Daily - Mon Nov 17, 2:13PM CST
Stocks remained mixed late Monday afternoon as investors weighed a spate of merger activity against news that Japan fell into a recession. The Dow Jones industrial average and the S&P 500 were each up 0.1%, while the Nasdaq was down 0.3%. Volume was...
AGN: 212.52 (+3.32), VRX: 140.97 (+4.24), ACT: 261.13 (+13.19), LNKD: 223.20 (-0.08), FB: 74.56 (+0.32), HAL: 49.90 (+0.67), BHI: 66.08 (+0.85), Z: 119.71 (+1.85)
Stock Market Today: Stocks Are Mixed as Corporate Deals Offset Japan's Recession
at The Street - Mon Nov 17, 12:16PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies distract Wall Street from worrying news Japan had fallen into recession in its third quarter.
AGN: 212.69 (+3.49), HAS: 56.16 (-0.21), AMZN: 326.88 (+3.83), VRX: 140.97 (+4.24), ACT: 261.25 (+13.31), LNKD: 223.22 (-0.06), JIVE: 6.37 (unch), FB: 74.56 (+0.32), HAL: 49.90 (+0.67), DWA: 22.59 (+0.28), CRM: 63.16 (+0.65), BHI: 66.08 (+0.85)
Pershing Square wins big on Actavis buy
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:22AM CST
AGN: 212.69 (+3.49), ACT: 261.09 (+13.15), VRX: 140.97 (+4.24)
Cramer: Investors Should Ignore Analysts' Calls on Hotel, Other Stocks
at The Street - Mon Nov 17, 10:32AM CST
Analysts have been growing pessimistic on several high quality stocks and sectors. Investors should use weakness as a buying opportunity instead, Cramer said.
AGN: 212.69 (+3.49), ACT: 261.10 (+13.16), PG: 87.83 (-0.01), MAR: 76.94 (-0.23), HOT: 77.22 (+0.37)
Allergan's $66 Billion Actavis Deal is Still a Win for Bill Ackman
at The Street - Mon Nov 17, 9:59AM CST
Valeant says it can't justify $219 a share offer to shareholders.
ZTS: 44.06 (-0.17), AGN: 212.69 (+3.49), VRX: 140.97 (+4.24), ACT: 261.10 (+13.16)
Stock Market Today: Stocks Shrug Off Japan's Recession as Deals Dominate Day
at The Street - Mon Nov 17, 9:40AM CST
U.S. stocks recover from earlier lows triggered by Japan's recession. Deals news about Baker Hughes and Allergan dominate headlines.
AGN: 212.69 (+3.49), HAS: 56.16 (-0.21), ACT: 261.14 (+13.20), HAL: 49.90 (+0.67), DWA: 22.59 (+0.28), BHI: 66.07 (+0.84)
ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Mon Nov 17, 9:32AM CST
Rigrodsky & Long, P.A.:
AGN: 212.59 (+3.39), ACT: 261.13 (+13.19)
Actavis Nabs Allergan For $66 Billion; Valeant Folds
at Investor's Business Daily - Mon Nov 17, 9:17AM CST
One of the most widely rumored deals in pharma came to fruition Monday, as Actavis (ACT) agreed to acquire Allergan (AGN) for $66 billion in cash and stock. Allergan stock was up more than 7%, near 213, and Actavis stock up nearly 4%, near 253, in...
AGN: 212.68 (+3.48), VRX: 140.97 (+4.24), ACT: 260.76 (+12.82)
Time to move on: Valeant chief says $219 too rich
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 9:13AM CST
ACT: 261.05 (+13.11), VRX: 140.97 (+4.24)
Valeant Comments On Allergan Announcement
PR Newswire - Mon Nov 17, 8:29AM CST
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock.
AGN: 212.68 (+3.48), ACT: 261.05 (+13.11), VRX: 140.97 (+4.24), VRX.TO: 159.49 (+5.09)
It's official: Actavis buys Allergan
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:26AM CST
AGN: 212.68 (+3.48), ACT: 261.07 (+13.13)
(0)
(0)Allergan plc (AGN) Stock Research Links
Scroll down for more posts ▼